{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:39:30Z","timestamp":1790710770244,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bcp.2018.07.021","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T09:42:30Z","timestamp":1531906950000},"page":"264-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential"],"prefix":"10.1016","volume":"155","author":[{"given":"N.M.","family":"Pathak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.A.","family":"Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"McClean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.bcp.2018.07.021_b0005","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.4239\/wjd.v6.i15.1285","article-title":"New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders","volume":"6","author":"Irwin","year":"2015","journal-title":"World J. Diabetes"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.021_b0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4093\/dmj.2016.40.2.99","article-title":"An update on the effect of incretin-based therapies on \u03b2-cell function and mass","volume":"40","author":"Chon","year":"2016","journal-title":"Diabetes Metab. J."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.021_b0015","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.bcp.2018.07.021_b0025","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2337\/db06-1033","article-title":"Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes","volume":"56","author":"Xu","year":"2007","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.bcp.2018.07.021_b0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/dom.12227","article-title":"Effects of chronic exposure of clonal \u03b2-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1","volume":"16","author":"Pathak","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.021_b0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.bcp.2018.07.021_b0040","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bbrc.2007.08.115","article-title":"Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycaemia in the Zucker rat","volume":"362","author":"Piteau","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.021_b0045","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/VHRM.S3105","article-title":"New combination treatments in the management of diabetes: focus on sitagliptin-metformin","volume":"4","author":"Green","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.021_b0050","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bcp.2012.04.015","article-title":"Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25","volume":"84","author":"Martin","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.021_b0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mce.2015.11.019","article-title":"Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice","volume":"420","author":"Millar","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.021_b0060","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.1152\/ajpendo.00639.2009","article-title":"On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans","volume":"298","author":"Asmar","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2018.07.021_b0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1042\/CS20110006","article-title":"Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity","volume":"121","author":"Gault","year":"2011","journal-title":"Clin. Sci. (Lond.)"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.021_b0070","first-page":"319","article-title":"Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells","volume":"1425","author":"O'Harte","year":"1998","journal-title":"BBA"},{"key":"10.1016\/j.bcp.2018.07.021_b0075","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2337\/diabetes.51.3.652","article-title":"Dipeptidyl peptidase IV-resistant [d-Ala2]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats","volume":"51","author":"Hinke","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2018.07.021_b0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.regpep.2012.12.012","article-title":"The C-terminal extension of exendin 4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs","volume":"10","author":"Simonsen","year":"2013","journal-title":"Regul. Pept."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1476-5381.2011.01687.x","article-title":"The structure and function of the glucagon-like peptide-1 receptor and its ligands","volume":"166","author":"Donnelly","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2018.07.021_b0090","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1463-1326.2010.01259.x","article-title":"Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance","volume":"12","author":"Porter","year":"2010","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.021_b0095","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejphar.2010.10.059","article-title":"Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice","volume":"650","author":"Porter","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.021_b0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuropharm.2014.06.026","article-title":"Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice","volume":"86","author":"Lennox","year":"2014","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/WNR.0000000000000490","article-title":"A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat","volume":"27","author":"Han","year":"2016","journal-title":"Neuroreport"},{"issue":"11","key":"10.1016\/j.bcp.2018.07.021_b0110","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/ijms18112493","article-title":"The role of glucagon-like peptide 1 (GLP1) in type 3 diabetes: GLP-1 controls insulin resistance, neuroinflammation and neurogenesis in the brain","volume":"18","author":"Bae","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.021_b0115","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.bcp.2009.05.037","article-title":"Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties","volume":"78","author":"Kerr","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.021_b0120","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00125-014-3296-7","article-title":"A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation","volume":"57","author":"Lynch","year":"2014","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.bcp.2018.07.021_b0125","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2337\/diab.45.8.1132","article-title":"Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion","volume":"45","author":"McClenaghan","year":"1996","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.bcp.2018.07.021_b0130","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00252768","article-title":"Abnormal plasma glucose and insulin responses in heterozygous lean (ob\/+) mice","volume":"20","author":"Flatt","year":"1981","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.021_b0135","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/dom.12300","article-title":"Evidence for inhibitory autocrine effects of proinsulin C-peptide on pancreatic \u03b2-cell function and insulin secretion","volume":"16","author":"McKillop","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"49","key":"10.1016\/j.bcp.2018.07.021_b0140","doi-asserted-by":"crossref","first-page":"35581","DOI":"10.1074\/jbc.M113.512046","article-title":"A novel glucagon-like peptide-1 (GLP-1)\/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice","volume":"288","author":"Gault","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.07.021_b0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.peptides.2017.10.015","article-title":"A novel GLP-1\/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice","volume":"100","author":"Hasib","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.bcp.2018.07.021_b0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mce.2015.05.035","article-title":"Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice","volume":"412","author":"Pathak","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.021_b0160","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/psc.861","article-title":"Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob\/ob) mice","volume":"13","author":"Irwin","year":"2007","journal-title":"J. Pept. Sci."},{"issue":"30","key":"10.1016\/j.bcp.2018.07.021_b0165","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1074\/jbc.M117.781047","article-title":"Temporal characterization of \u03b2 cell-adaptive and -maladaptive mechanisms during chronic high-fat feeding in C57BL\/6NTac mice","volume":"292","author":"Gupta","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0170","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.bcp.2018.07.021_b0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1530\/JOE-17-0263","article-title":"Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice","volume":"234","author":"Millar","year":"2017","journal-title":"J. Endocrinol."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.021_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126769","article-title":"The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis","volume":"10","author":"Potts","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bcp.2018.07.021_b0185","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2008.08.052","article-title":"Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice","volume":"376","author":"Naitoh","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.021_b0195","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00125-009-1422-8","article-title":"Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications","volume":"52","author":"Irwin","year":"2009","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.bcp.2018.07.021_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040156","article-title":"GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dom.13034","article-title":"A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents","volume":"20","author":"N\u00f8rregaard","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.021_b0210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"209","key":"10.1016\/j.bcp.2018.07.021_b0215","doi-asserted-by":"crossref","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1463-1326.2009.01073.x","article-title":"The effects of glucagon-like peptide-1 on the beta cell","volume":"11","author":"Vilsb\u00f8ll","year":"2009","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.021_b0225","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1007\/s00125-017-4303-6","article-title":"GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in \u03b2IRKO mice","volume":"60","author":"Kawamori","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.bcp.2018.07.021_b0230","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1124\/jpet.105.086082","article-title":"A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes","volume":"314","author":"Irwin","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.021_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009590","article-title":"A GIP receptor agonist exhibits \u03b2-cell anti-apoptotic actions in rat models of diabetes resulting in improved \u03b2-cell function and glycemic control","volume":"5","author":"Widenmaier","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/dom.12181","article-title":"A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents","volume":"16","author":"Tatarkiewicz","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.021_b0245","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2337\/dc12-2504","article-title":"A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks","volume":"36","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2018.07.021_b0250","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/B978-0-12-381517-0.00013-8","article-title":"The role of GLP-1 in neuronal activity and neurodegeneration","volume":"84","author":"H\u00f6lscher","year":"2010","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.bcp.2018.07.021_b0255","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.regpep.2014.05.002","article-title":"Peptide drugs that have been developed to treat type 2 diabetes show neuroprotective effects","volume":"193","author":"Holscher","year":"2014","journal-title":"Regul. Pept."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0260","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3892\/mmr.2015.3447","article-title":"Effects of glucose-dependent insulinotropic polypeptide receptor knockout and a high-fat diet on cognitive function and hippocampal gene expression in mice","volume":"12","author":"Lennox","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.021_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5455\/jeim.050216.br.027","article-title":"(D-Ser2)Oxm[Lys38-\u03b3-glu-PAL] improves hippocampal gene expression and cognition in a mouse model of type 1 diabetes","volume":"6","author":"Pathak","year":"2016","journal-title":"Exp. Integr. Med."},{"key":"10.1016\/j.bcp.2018.07.021_b0270","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer's disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.07.021_b0275","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.07.021_b0280","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/717958","article-title":"Involvement of adult hippocampal neurogenesis in learning and forgetting","volume":"2015","author":"Yau","year":"2015","journal-title":"Neural Plast."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2018.07.021_b0285","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejphar.2011.11.007","article-title":"Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice","volume":"674","author":"Faivre","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"A","key":"10.1016\/j.bcp.2018.07.021_b0290","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer's disease","volume":"76","author":"McClean","year":"2014","journal-title":"Neuropharmacology"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T04:18:39Z","timestamp":1576815519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218302892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":57,"alternative-id":["S0006295218302892"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.021","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}